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Abstract 
Background: Treatment options for drug‑resistant tuberculosis are still limited. Linezolid has been recommended for 
treatment of patients with multidrug‑resistant (MDR) or extensively‑drug‑resistant (XDR) tuberculosis, although uncer‑
tainties remain regarding its safety and tolerability in these circumstances.
Objective: To systematically evaluate the existing evidence regarding the efficacy and tolerability of linezolid in the 
treatment of MDR or XDR tuberculosis.
Methods: We conducted a systematic review and meta‑analysis in accordance with the PRISMA guidelines. Searches 
were conducted in PubMed, Web of Science and EMBASE followed by direct search of abstracts in the International 
Journal of Tuberculosis and Lung Disease to retrieve primary studies published between January 2000 and January 
2016 assessing linezolid efficacy and safety in the treatment of drug‑resistant TB. We evaluated the occurrence of 
outcomes including culture conversion, treatment success and incidence of adverse events such as myelosuppres‑
sion and neuropathy.
Results: Twenty‑three (23) studies conducted in fourteen (14) countries and involving 507 patients were retrieved. 
Only 1 randomized controlled trial was identified and none of the identified studies involved participants from Africa. 
The pooled proportion for treatment success was 77.36 % (95 % CI = 71.38–82.83 %, I2 = 37.6 %) with culture conver‑
sion rate determined as 88.45 % (95 % CI = 83.82–92.38 %, I2 = 45.4 %). There was no strong evidence for both culture 
conversion (p = 0.0948) and treatment success (p = 0.0695) between linezolid daily doses ≤ 600 and > 600 mg. Only 
myelosuppression showed a strong statistical significance (p < 0.0001) between dose comparisons. The incidence of 
neuropathy and other adverse events leading to permanent discontinuation of linezolid also showed no significance 
upon dose comparisons (p = 0.3213, p = 0.9050 respectively).
Conclusion: Available evidence presents Linezolid as a viable option in the treatment of MDR/XDR TB although 
patients ought to be monitored closely for the incidence of major adverse events such as myelosuppression and 
neuropathy. Additionally, highly powered randomized controlled trials including participants from endemic regions 
are urgently needed to better inform the magnitude and significance of Linezolid treatment effect in MDR and XDR 
TB patients.
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Background
Tuberculosis (TB) is a significant contributor to global 
morbidity and mortality. About one in three persons 
representing almost 3 billion individuals worldwide are 
known to be infected with Mycobacterium tuberculo-
sis of which at least 5  % are  likely to develop active TB 
disease during their lifetime [1, 2]. In 2014, more than 9 
million new cases of TB were recorded resulting in over 
1.5 million deaths [2]. Nearly one in three deaths in HIV-
positive individuals are attributable to TB [3]. Dispropor-
tionate number of global TB cases are known to occur in 
areas such as Sub-Saharan Africa and South East Asia [2]. 
The economic impact of TB is deemed to be enormous as 
more than 90 % of TB-related deaths occur among adults 
in the most productive years [4].
Over the last few years, significant progress has been 
made towards controlling TB and reducing the global 
burden of the disease. TB incidence has declined in all 
parts of the world by at least 1.5  % annually since 2000 
and is now almost 18  % lower than the rate in 2000 [1, 
5]. Additionally, TB mortality has decreased by almost 
50 % since 1990, with nearly all of that improvement hap-
pening in the era of the millennium development goals 
(MDGs) [5]. In the context of these TB control successes, 
it is estimated that over 40 million lives were saved in the 
period 2000–2014 [1].
However, in spite of the positive developments, the 
increasing emergence of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) TB across the globe has 
the potential to derail the fight against TB and possibly 
revert the progress made regarding TB care and control. 
MDR-TB has been used to represent all forms TB disease 
in which the causative bacteria is resistant to at least iso-
niazid and rifampicin, whereas XDR-TB denotes forms 
of TB in which the bacteria is resistant to rifampicin and 
isoniazid plus any fluoroquinolone, and at least one of the 
second line injectable TB drugs (i.e., amikacin, kanamycin, 
or capreomycin) [6]. By the end of 2013, over 90 countries 
had documented at least a case of XDR-TB [7]. Almost 
5 % of all global TB cases are now estimated to be MDR-
TB including over 3 % of newly diagnosed TB cases, and as 
much as 20 % in previously treated patients [8, 9]. In 2014 
alone, more than 400,000 cases of MDR-TB were reported 
with nearly 10 % of this being XDR-TB [8].
The cost implication of MDR/XDR TB is enormous 
and one that could impose significant strain on any 
healthcare system. Diel et al., for instance, estimated the 
total cost per MDR-TB and XDR-TB case in Germany 
to be €82,150 and €108,733, respectively [10]. Within 
the period 2011–2015, as much as USD 1.7 billion was 
required across the world in tackling MDR-TB [11].
Treatment outcomes for MDR/XDR-TB remain poor 
even in advanced health systems. In 2007, the World 
Health Organization (WHO) reported that just around 
one-third of the over 7000 MDR-TB patients from 13 
countries were successfully treated [12]. On the other 
hand, for nearly four decades no new anti -tubercu-
lar drug was registered until the recent introduction of 
Delamanid and Bedaquiline [13, 14]. Even these new 
drugs are unable to resolve all the challenges regarding 
therapy for MDR/XDR-TB [14]. In view of this, diverse 
treatment approaches have continually been explored 
including the use of therapies containing linezolid, 
higher doses of isoniazid and sometimes fluoroquinolo-
nes [15].
Linezolid an Oxazolidinone and a relatively newer class 
of antibiotic has demonstrated potency against drug-
resistant M. tuberculosis in a number of in vitro studies 
[16–18]. Since 2006, the WHO has recommended the 
use of linezolid in the treatment of MDR/XDR-TB with 
the drug now being included in many TB programmes 
across the world [19, 20]. Aside its high cost which 
remains a major barrier to access, there are uncertainties 
regarding the most effective dose of linezolid with < 600 
or ≥  600  mg daily doses being documented in separate 
reports [19, 21]. Additionally, serious adverse effects 
such as neuropathies and hematological adverse reac-
tions have been reported raising huge concerns about the 
safety of the drug in the treatment of XDR and MDR-TB 
which usually demands extensive treatment periods [19, 
21].
Some reviews have previously sought to assess the effi-
cacy and tolerability/safety of linezolid in the treatment 
of MDR/XDR-TB [19–23]. The latest of these reviews 
conducted by Zhang et al. [23], includes primary studies 
published no later than May 2014. Considering that sci-
entific evidence changes rapidly and according to Whit-
lock et al. [24], reviews are deemed to be out of date often 
after few years, there is the need for continuous evalua-
tion of evidence to incorporate new information as they 
become available. In view of this, we conducted a system-
atic review and meta-analysis to summarize the existing 
evidence to date of the safety and efficacy of linezolid in 
the treatment of DR-TB as an update to previously con-
ducted reviews.
Methods
This systematic review was conducted in accordance with 
the PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) guidelines [25].
Search strategy and study selection
We performed searches in PubMed, Web of Science and 
EMBASE for relevant studies published between Janu-
ary 2000 and January 2016. In addition, we searched the 
International Journal of Tuberculosis and Lung Disease 
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for original studies published on the subject within the 
above period. A combination of key words and their 
synonyms used in all searches were ‘multidrug resistant 
tuberculosis’, ‘extensively drug resistant tuberculosis’, ‘lin-
ezolid’, ‘zyvox’, ‘efficacy’ and ‘toxicity’. We included ‘zyvox’ 
as a keyword as it is the most commonly marketed brand 
name for linezolid [26]. Search results were limited to 
human population and English language. References of 
selected studies  and previously published reviews were 
also screened to identify additional publications. We 
included only published primary studies involving adult 
populations of  ≥5 patients with sputum culture con-
firmed (pulmonary or extra pulmonary TB) and avail-
able report on efficacy and tolerability  (safety). In  vitro 
studies and review articles were excluded as well as case 
reports with sample size less than 5 patients. Exclusion 
of  studies with relatively small sample size was intended 
to minimize selection and reporting bias [27].
Study quality assessment
We employed the McMaster critical review for quantita-
tive studies to critically appraise all studies [28, 29]. Fur-
ther methodological quality assessments of studies were 
conducted based on the following criteria: linezolid dose 
stated, DST guided treatment regimen, hospitalization at 
initiation of linezolid treatment, IRB approval obtained, 
patients monitored by DOT and outcomes report similar 
to WHO definitions.
Data extraction
A data extraction form was developed and used to guide 
the extraction of data from the included studies. First 
author name, publication year, duration of study, type of 
study design, control group present, country of study and 
number of HIV co-infected patients were extracted for 
epidemiological characteristics. With regards to efficacy 
and tolerability, data extracted included total number of 
MDR/XDR TB exposed to linezolid, treatment regimen 
employed and linezolid dose. Outcome measures on effi-
cacy and tolerability were based on WHO definitions 
[30]. For efficacy, data were extracted for patients who 
achieved sputum culture conversion to negative as well as 
those who were cured. Patients who defaulted, achieved 
treatment failure, relapsed or died were regarded as unfa-
vorable outcomes. For tolerability, data were extracted 
for neuropathy, myelosuppression, both temporary and 
permanent discontinuation of linezolid due to adverse 
effects and other reported adverse effects associated 
with linezolid [31]. A summary of the data for outcomes 
evaluation has been provided as a supplementary mate-
rial (Additional file 1).  All data were extracted by AA and 
verified by RO. Where there were disagreements, these 
were resolved by consensus-based discussions.
Statistical analysis
The meta-analysis proportions were conducted using 
StatsDirect statistical software (Version 3.0.0, StatsDi-
rect Ltd, Cheshire UK) [32]. Individual study propor-
tions were assessed at 95  % confidence interval (CI) as 
well as the pooled effect. Between-study heterogeneity 
was assessed by the Quoran (Q) statistic test and the I2 
statistic, which represents the percentage of total varia-
tion across studies, attributable to heterogeneity rather 
than to chance [33]. As we anticipated variations among 
studies for multiple reasons including study conduct 
methods, the random effect model (DerSimonian-Laird) 
was adopted over fixed effect model in the summary of 
pooled analysis [33]. Publication bias was evaluated by 
direct observation of   funnel plots and the Egger and 
Begg’s tests were applied to measure any asymmetry [34]. 
For all computations statistical significance was set at 
p < 0.05.
Ethical approval
Ethical approval was not sought for this study as all infor-
mation used were derived from already published studies 
available in the public domain.
Results
Studies identification and retrieval
A total of 469 records were retrieved from database 
search in addition to two records identified through 
International Journal of Tuberculosis and Lung Dis-
ease. Upon removing duplicates and screening by titles 
and abstracts, 46 articles were found relevant for full-
text analysis and reference list screening. Subsequent to 
this, 23 articles were excluded with reasons (Fig. 1) and 
23 studies were identified as eligible for inclusion in the 
meta-analysis [35–57]. The 23 studies were conducted in 
14 countries across the globe. Per regional distribution, 
more than half (57 %, n = 13), were conducted in Asia. 
The rest of the studies were conducted in North Amer-
ica (n = 4), South America (n = 1) and Europe (n = 5). 
None of the selected studies was conducted in Africa. 
About 57  % (n  =  13) of studies were conducted in the 
last 5  years (2011–2016). Most of the studies were case 
series (n  =  20, 87  %). Only one randomized controlled 
trial was identified [51]. The two remaining studies con-
sisted of one non-randomized Phase 1 clinical trial [36] 
and the other a Phase 2a clinical trial [42]. A total of 507 
patients received linezolid as part of their treatment regi-
men and 353 patients were evaluated for definite out-
comes (cured, treatment completed, died, failure). About 
57 % of patients enrolled tested positive for XDR TB and 
3 % had documented HIV positive status (Table 1). Thus 
the population involved was predominantly HIV nega-
tive. In most of the studies, linezolid was included in the 
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treatment regimen based on DST following treatment 
failure to previous treatment regimen. Linezolid was gen-
erally administered at a daily minimum dose of 300 mg to 
a maximum dose of 1200 mg. The duration of treatment 
ranged from 1 to 36  months. The quality assessment 
across studies was generally satisfactory. All studies indi-
cated linezolid dose and treatment regimen was individu-
alized based on DST results (Table  2). However, 19 out 
of 23 studies reported Institutional Review Board (IRB) 
approval prior to study initiation. The remaining four 
studies did not report on IRB approval [38, 43, 45, 58]. 
Hospitalization prior to linezolid treatment was poorly 
reported; no reporting was done by 15 studies. None-
theless, 6 studies reported patient hospitalization prior 
to linezolid treatment and only 2 studies indicated no 
patient hospitalization. Also, DOT was not reported in 
12 out of 13 studies. With respect to treatment success, 
sixteen (16) studies were similar to WHO definitions 
whiles four (4) studies did not conform to WHO stand-
ards and three (3) studies did not report on their refer-
ence guideline.
Efficacy
With the exception of Udwadia et  al. [53], all the stud-
ies reported on sputum culture conversion with a 
pooled proportion of 88.45 % (95 % CI = 83.82–92.38 %, 
p =  0.0112) (Fig.  2) and moderate heterogeneity across 
studies (I2 = 45.4 %; 95 % CI = 0–65.9 %). Eight studies 
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Fig. 1 A schematic flow diagram of studies’ search and retrieval process
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[35, 36, 39, 46, 48, 50, 54, 55], achieved 100  % sputum 
culture conversion with a total number of 98 out of 507 
patients exposed to linezolid. Among these eight studies, 
three studies [35, 39, 55] administered linezolid at a dose 
of 600 mg twice daily with only one study administering 
at a dose of 600 mg daily. The remaining four studies had 
mixed dosing regimen in the same cohort of patients. A 
total of 274 patients achieved treatment success across 
the 23 studies with a combined proportion of 77.36  % 
(95 % CI = 71.38–82.83 %, p = 0.0365) (Fig. 3) and a low 
homogeneity test result of 37.6 % (95 % CI = 0–61.3 %). 
Only two studies [38, 46] had less than 50  % treatment 
success with linezolid dose regimen between 600 and 
1200 mg daily. Three studies [35, 37, 52] reported 100 % 
treatment success (95 % CI = 78.20–100, 54.07–100 and 
66.37–100 %, respectively).
Safety and tolerability
Adverse events related to Linezolid was observes in all 
the studies. Major adverse events leading to permanent 
discontinuation of linezolid was observed in 21 stud-
ies with pooled proportion of 15.81 % (95 % CI = 9.68–
23.11 %, p < 0.0001) (Fig. 4). Heterogeneity was observed 
to be very high at 74  % (95  % CI =  58.0–82.0  %). Two 
studies did not report whether any permanent discon-
tinuation due to linezolid toxicity had happen or not 
[53, 54]. On the other hand, in five studies there was no 
occurrence of permanent discontinuation of linezolid due 
to adverse events in patients [35, 37, 38, 50, 57]. All 23 
studies reported myelosuppression in the form of anemia 
or neutropenia. The pooled proportion of myelosuppres-
sion was observed at 32.93 % (95 % CI = 23.13–43.54 %, 
p < 0.0001) (Fig. 5) and high heterogeneity of 83 %. The 
Canadian cohort [52] recorded the highest incidence of 
myelosuppression of 85 % (11 out 13 patients) at a line-
zolid dose of 600  mg daily. Koh et  al. [40] recorded the 
least occurrence of myelosuppression; 4  % (1 out of 24 
patients) with daily 300  mg dose of linezolid. Neuropa-
thy was also recorded in all but one studies with a com-
bined proportion of 29.92 % (95 % CI = 20.53–40.25 %, 
Table 2 Summary of the methodological quality assessment of included studies
Study  
No.















1. Abbate et al. [35] Yes Yes Yes NR NR Yes
2. Anger et al. [36] Yes Yes Yes NR Yes Yes
3. Condos et al. [37] Yes Yes Yes NR NR Yes
4. De Lorenzo et al. 
[38]
NR Yes Yes NR NR Yes
5. Fortún et al. [39] Yes Yes Yes NR Yes Yes
6. Koh et al. [40] Yes Yes Yes NR Yes Yes
7. Koh et al. [41] Yes Yes Yes NR NR Yes
8. Lee et al. [42] Yes Yes Yes Yes Yes No
9. Liu et al. [43] NR Yes Yes Yes NR NR
10. Migliori et al. [44] Yes Yes Yes NR Yes Yes
11. Nam et al. [45] NR Yes Yes NR NR No
12. Park et al. [46] Yes Yes Yes NR NR Yes
13. Roongruangpitay‑
akul et al. [47]
Yes Yes Yes No Yes Yes
14. Schecter et al. [48] Yes Yes Yes NR Yes Yes
15. Singla et al. [49] Yes Yes Yes Yes Yes No
16. Tang et al. [50] Yes Yes Yes NR NR NR
17. Tang et al. [51] Yes Yes Yes NR Yes Yes
18. Tse‑Chang et al. 
[52]
NR Yes Yes NR NR Yes
19. Udwadia et al. [53] Yes Yes Yes No NR NR
20. Villar et al. [54] Yes Yes Yes NR NR Yes
21. Von der Lippe 
et al. [55]
Yes Yes Yes Yes Yes No
22. Xu et al. [56] Yes Yes Yes Yes Yes Yes
23. Zhang et al. [57] Yes Yes Yes Yes NR Yes
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p  <  0.0001) (Fig.  6). None of the patients enrolled in 
Fortun et  al. experienced neuropathy and Linezolid was 
given at a dose of 600 mg BD [39]. The highest propor-
tion of neuropathy was observed in Nam et al. [45] with a 
proportion of 81.82 % (95 % CI = 48.22–97.72 %) where 
linezolid was administered at a maximum dose of 600 mg 
daily. With the exception of Von der Lippe et  al. [55], 
adverse events other than myelosuppression and neurop-
athy were reported in the remaining 22 studies. Nausea 
and vomiting were the most frequently reported. Others 
included hyperpigmentation of the oral cavity [51] and 
transient visual impairment [47]. The pooled proportion 
of reported adverse events other than myelosuppression 
and neuropathy was 33.60 % (95 % CI = 20.41–48.23 %, 
p < 0.0001) (Fig. 7).
Outcomes comparison between daily doses ≤ 600 
and > 600 mg
Patients receiving linezolid at a dose ≤ 600 mg had lower 
proportions (85.58  %) of culture conversion compared 
to those receiving linezolid at doses > 600 mg (95.12 %). 
There was no strong evidence for both culture conversion 
(p = 0.0948) and treatment success (p = 0.0695) between 
linezolid doses ≤ 600 and > 600 mg (Table 3). Nonethe-
less, higher proportion of patients achieved treatment 
success in higher doses of linezolid (89.47 %) compared 
to administering lower doses of linezolid (76.14 %). Lin-
ezolid doses  >  600  mg observed higher incidence of 
myelosuppression (50 %) compared with doses ≤ 600 mg 
(19.58 %). Only myelosuppression showed a strong statis-
tical significance (p < 0.0001) between dose comparisons. 
Fig. 2 Forest plot of culture conversion, individual and pooled (random effects)
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On the contrary, the incidence of neuropathy and adverse 
events leading to permanent discontinuation of lin-
ezolid showed no significance upon dose comparisons 
(p = 0.3213, p = 0.9050 respectively).
Publication bias
Begg’s and Egger’s regression tests were performed to 
assess publication bias. The shapes of the funnel plots 
do not show obvious evidence of asymmetry (Fig.  8). 
However, the p value of Egger’s test confirmed the exist-
ence of publication bias for all the outcomes evaluated 
[(A) Culture conversion, p =  0.0144; (B) treatment suc-
cess, p = 0.0006; (C) myelosuppression, p = 0.0295; (D) 
neuropathy p  =  0.0014; (E) discontinuation due to lin-
ezolid adverse effects, p =  0.01 and (F) presence of any 
other adverse events, p = 0.0067].
Discussion
This systematic review and meta-analysis included a 
larger number of case reports and observational studies 
than reported in previous reviews which suggests that 
linezolid is increasingly being used off-label in the man-
agement of drug resistant TB. In our systematic review, 
only one randomized controlled trial (with ‘no linezolid 
intervention’ control group) conducted by Tang et  al. 
[51] in China was identified with a total sample size of 
0.0 0.2 0.4 0.6 0.8 1.0
Proporon meta-analysis plot [random effects]
combined 0.77 (0.71, 0.83)
Zhang et al. (2014) 0.60 (0.32, 0.84)
Xu et al. (2012) 0.82 (0.48, 0.98)
Von der Lippe et al. (2006) 0.90 (0.55, 1.00)
Villar et al.(2011) 0.89 (0.52, 1.00)
Udwadia et al. (2010) 0.61 (0.36, 0.83)
Tse-Chang et al. (2013) 1.00 (0.66, 1.00)
Tang et al. (2015) 0.79 (0.60, 0.92)
Tang et al. (2011) 0.79 (0.49, 0.95)
Singla et al. (2012) 0.64 (0.35, 0.87)
Schecter et al. (2010) 0.88 (0.69, 0.97)
Roongruangpitayakul et al (2013) 0.88 (0.64, 0.99)
Park et al.(2006) 0.33 (8.4E-3, 0.91)
Nam et al. (2009) 0.55 (0.23, 0.83)
Migliori et al. (2009) 0.80 (0.65, 0.90)
Liu et al (2015) 0.85 (0.55, 0.98)
Lee et al. (2012) 0.76 (0.50, 0.93)
Koh et al. (2012) 0.76 (0.60, 0.87)
Koh et al. (2009) 0.67 (0.22, 0.96)
Fortun et al. (2005) 0.50 (0.01, 0.99)
De Lorenzo et al. (2012) 0.33 (8.4E-3, 0.91)
Condos et al. (2008) 1.00 (0.54, 1.00)
Anger et al. (2010) 0.69 (0.41, 0.89)
Abbate et al. (2012) 1.00 (0.78, 1.00)
proporon (95% confidence interval)
Fig. 3 Forest plot of treatment success, individual and pooled (random effects)
Page 10 of 17Agyeman and Ofori‑Asenso  Ann Clin Microbiol Antimicrob  (2016) 15:41 
65 patients. This is the first of such kind compared to the 
randomized trials reported by Lee et al. [42] where both 
study groups were administered linezolid.
Efficacy
In our review, linezolid was administered in combination 
with other anti-tubercular drugs to achieve treatment 
success. Thus treatment success may not be exclusively 
attributed to linezolid. Nonetheless, since linezolid inclu-
sion mostly followed resistance or treatment failure with 
other second line drugs, much of the treatment success 
may be attributed to linezolid. We obtained a pooled 
culture conversion of 88.45  % (95  % CI 83.82–92.38  %, 
p  =  0.0112). Previous reviews by Sotgui et  al. [22] and 
Zhang et  al. [23] obtained pooled culture conversion 
of 93  % (p  =  0.2704) and 89  % (p  =  0.0217) respec-
tively. The results from our study shows strong evidence 
(p = 0.0112) of linezolid to achieve culture conversion in 
MDR/XDRTB patients which is synonymous to that from 
Zhang et al. (p = 0.0217) [23] due to large samples size in 
these studies compared to Sotgui et al. [22] whose results 
depicted otherwise.
On the other hand, pooled treatment success was 
significantly lower [77.36  % (95  % CI 71.38–82.83  %, 
p  =  0.0365)] than that obtained for culture conver-
sion. This is also similar to the stated cure rates in the 
2015 WHO Global TB report and also results obtained 
from previous reviews [1, 19, 22, 23]. The 2015 WHO 
Global report on TB, reports cure rates in 2014 from 
43 countries as ≥  75 % with global average cure rate of 
50 %. The treatment success proportion obtained in our 
review in comparison with the culture conversion signifi-
cantly implies that, most of the MDR/XDR TB patients 
who achieve sputum culture conversion do not achieve 
Fig. 4 Forest plot of discontinuation due to linezolid adverse effects, individual and pooled (random effects)
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treatment success. This may be due to default, treat-
ment failure, treatment discontinuation due to adverse 
effects or relapse. In a study conducted by Xu et al. [56], 
all patients (n = 18) administered linezolid were culture 
negative at 7 weeks of treatment during hospital admis-
sion. However, at data censor after patient discharge from 
the hospital, only nine patients (50  %) achieved treat-
ment success whiles three and two patients relapsed and 
attained treatment failure, respectively. Synonymously, 
five studies [42, 43, 49, 55, 56] which reported patient 
admission prior to linezolid administration and discharge 
after culture conversion also observed higher propor-
tions of culture conversion than treatment success.
Fifteen studies (Table 2) did not report on hospitaliza-
tion whiles two studies initiated linezolid under outpa-
tient environment [47, 53]. One out of these two studies 
obtained a lower treatment success (61.10 %) compared 
to the other [47, 53]. These results contribute to the sig-
nificance of hospitalization prior to treatment initia-
tion in MDR/XDR TB which enhances therapeutic and 
adverse events monitoring as well as patient compli-
ance to therapy to achieve high proportions of treatment 
0.0 0.2 0.4 0.6 0.8 1.0
Proporon meta-analysis plot [random effects]
combined 0.33 (0.23, 0.44)
Zhang et al. (2014) 0.27 (0.08, 0.55)
Xu et al. (2012) 0.72 (0.47, 0.90)
Von der Lippe et al. (2006) 0.50 (0.19, 0.81)
Villar et al.(2011) 0.13 (0.02, 0.38)
Udwadia et al. (2010) 0.06 (1.4E-3, 0.27)
Tse-Chang et al. (2013) 0.85 (0.55, 0.98)
Tang et al. (2015) 0.79 (0.61, 0.91)
Tang et al. (2011) 0.43 (0.18, 0.71)
Singla et al. (2012) 0.34 (0.18, 0.54)
Schecter et al. (2010) 0.07 (8.2E-3, 0.22)
Roongruangpitayakul et al (2013) 0.13 (0.03, 0.32)
Park et al.(2006) 0.13 (3.2E-3, 0.53)
Nam et al. (2009) 0.18 (0.02, 0.52)
Migliori et al. (2009) 0.27 (0.18, 0.38)
Liu et al (2015) 0.38 (0.15, 0.65)
Lee et al. (2012) 0.18 (0.08, 0.34)
Koh et al. (2012) 0.20 (0.10, 0.33)
Koh et al. (2009) 0.04 (1.1E-3, 0.21)
Fortun et al. (2005) 0.67 (0.09, 0.99)
De Lorenzo et al. (2012) 0.17 (0.02, 0.48)
Condos et al. (2008) 0.50 (0.12, 0.88)
Anger et al. (2010) 0.81 (0.54, 0.96)
Abbate et al. (2012) 0.24 (0.07, 0.50)
proporon (95% confidence interval)
Fig. 5 Forest plot of reported myelosuppression, individual and pooled (random effects)
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success. Nonetheless, Roongruangpitayakul et  al. [47] 
reports high treatment success proportion (88.2  %) 
obtained under outpatient conditions. This may imply 
that with efficient DOT, patients not requiring hospitali-
zation can also be successfully treated with linezolid as 
long as procedures are in place to monitor incidence of 
adverse events.
Administering different doses of linezolid did not show 
any significant difference in culture conversion and treat-
ment success; p = 0.0948 and p = 0.0695, respectively. A 
recent systematic review conducted by Zhang et al. also 
had similar results for culture conversion and favora-
ble outcomes, respectively [23]. Thus, linezolid may be 
administered at a lower dose to achieve treatment suc-
cess whiles reducing the incidence of adverse events. 
However, the dose and duration of linezolid in the treat-
ment of MDR/XDR TB ought to be streamlined based 
on evidence from randomized controlled trials (RCTs). 
An RCT conducted by Tang et al. and involving 65 XDR-
TB patients reported higher proportions of culture con-
version (96 vs. 41  %) and treatment success (79.31 vs. 
37.93 %) in the treatment group than the control group 
[51]. Also in this same RCT, patients were given an ini-
tial high dose of linezolid (1200 mg daily) for a period of 
4–6 weeks followed by a reduced dose (300–600 mg) in 
the continuous phase to complete a 24 month treatment 
regimen. This may propose a successful dosage regimen 
for MDR/XDR TB involving a maximum tolerable high 
dose of 1200  mg daily for a short intensive phase, fol-
lowed by a reduced dose between 300 and 600 mg daily 
during the continuous phase. Nonetheless, RCTs involv-
ing larger patient population need to be conducted to 
strengthen this evidence. Horsburg et al. proposes a novel 
method to ascertain optimum duration of antibiotic 
0.0 0.2 0.4 0.6 0.8 1.0
Proporon meta-analysis plot [random effects]
combined 0.30 (0.21, 0.40)
Zhang et al. (2014) 0.07 (1.7E-3, 0.32)
Xu et al. (2012) 0.61 (0.36, 0.83)
Von der Lippe et al. (2006) 0.60 (0.26, 0.88)
Villar et al.(2011) 0.06 (1.6E-3, 0.30)
Udwadia et al. (2010) 0.39 (0.17, 0.64)
Tse-Chang et al. (2013) 0.08 (1.9E-3, 0.36)
Tang et al. (2015) 0.42 (0.25, 0.61)
Tang et al. (2011) 0.21 (0.05, 0.51)
Singla et al. (2012) 0.17 (0.06, 0.36)
Schecter et al. (2010) 0.20 (0.08, 0.39)
Roongruangpitayakul et al (2013) 0.21 (0.07, 0.42)
Park et al.(2006) 0.50 (0.16, 0.84)
Nam et al. (2009) 0.82 (0.48, 0.98)
Migliori et al. (2009) 0.04 (7.3E-3, 0.10)
Liu et al (2015) 0.19 (0.04, 0.46)
Lee et al. (2012) 0.74 (0.57, 0.87)
Koh et al. (2012) 0.27 (0.16, 0.42)
Koh et al. (2009) 0.33 (0.16, 0.55)
Fortun et al. (2005) 0.00 (0.00, 0.71)
De Lorenzo et al. (2012) 0.17 (0.02, 0.48)
Condos et al. (2008) 0.33 (0.04, 0.78)
Anger et al. (2010) 0.44 (0.20, 0.70)
Abbate et al. (2012) 0.18 (0.04, 0.43)
proporon (95% confidence interval)
Fig. 6 Forest plot of reported neuropathy, individual and pooled (random effects)
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treatment regimen [58]. Their proposed model utilizes a 
logistic regression model in RCT design to ascertain the 
shortest possible antibiotic treatment duration in rela-
tion to corresponding proportions of cured patients. The 
researchers further highlighted the suitability of this pro-
posed model for anti-tubercular regimen with the aim of 
minimizing the incidence of resistance, toxicity, costs and 
pill burden [58].
Fig. 7 Forest plot of reported other adverse events, individual and pooled (random effects)








Culture conversion 184/215 (85.58) 39/41 (95.12) 9.54 (−2.29–16.32 %) p = 0.0948
Treatment success 134/176 (76.14) 34/38 (89.47) 13.34 (−13.22–23.12 %) p = 0.0695
Myelosuppression 47/240 (19.58) 24/48 (50.00) 30.42 (15.77–44.94 %) p < 0.0001
Neuropathy 82/240 (34.17) 20/48 (41.67) 7.5 % (−6.84–22.79 %) p = 0.3213
Linezolid discontinuation 40/222 (18.02) 9/48 (18.75) 0.73 % (−9.66–14.72 %) p = 0.9050
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Safety and tolerability
The major adverse events identified in this review were 
neuropathy and myelosuppression. Other minor adverse 
effects which were predominantly gastrointestinal 
related including nausea and vomiting were reported 
with a minimum pooled proportion of 33.60  % (95  % 
Fig. 8 Bias assessment (funnel) plots of publication bias for the outcomes evaluated (a culture conversion; b treatment success; c myelosuppres‑
sion; d neuropathy; e discontinuation due to linezolid adverse effects; f presence of any other adverse events)
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CI =  20.41–48.23  %). Only one case of rhabdomyolysis 
has been reported by Lee et al. [42] which is an important 
observation to note in case of an emerging rare adverse 
effects of linezolid. Myelosuppression occurred at a 
higher proportion than neuropathy with both adverse 
events bearing a significant association with linezolid 
with combined proportions of 32.93 and 29.92 % respec-
tively (p  <  0.0001). In most studies, myelosuppression 
and neuropathy effects were managed by temporarily 
or permanently (15.01  %, p  <  0.0001) discontinuing lin-
ezolid therapy. However, in some patients, incidence of 
severe anemia was remedied by blood transfusion [37]. 
Two cases were reported by Von der Lippe et  al. for 
attaining normal full blood count upon withdrawal of 
linezolid without having to undergo blood transfusion 
[55]. The incidence of myelosuppression was significantly 
dose related (p  <  0.0001) with lower doses associated 
with lower incidence. The incidence of neuropathy was 
reported in all studies except one [39]. Roongruangpitay-
akul et al. observed reversible optic neuropathy and irre-
versible peripheral neuropathy in patients who suffered 
these effects following treatment discontinuation and 
administration of vitamin B supplement [47]. Persistent 
irreversible neuropathy has also been previously reported 
by two other studies [53, 55]. From the results obtained 
(p = 0.52), neuropathy was not strongly associated with 
higher doses of linezolid and as such close monitoring of 
patients is encouraged irrespective of the dose adminis-
tered. Therefore, in order to improve tolerability of lin-
ezolid regimen in MDR/XDR TB, a combined high dose 
(1200  mg daily) aimed at a shorter duration and lower 
dose (300–600 mg) targeted at a longer continuous phase 
may be employed with effective patient monitoring to 
inform dose adjustments when required.
Strengths and limitations
The major strength of our study is the large patient pop-
ulation (n  =  507) which depicts a more significant and 
stronger evidence compared to previous reviews which 
included patient population of 218 [19], 121 [22] and 239 
[23]. However, there are limitations including the higher 
proportion of non-randomized case series and retro-
spective studies (n  =  21). This increases the likelihood 
of reporting and selection bias. Additionally, significant 
heterogeneity among studies are evident including pres-
ence of publication bias. Moreover, while this review pro-
vides some useful understanding regarding the safety and 
efficacy of linezolid, only 3 % of the patients involved in 
the studies’ reviewed had documented HIV positive sta-
tus. This calls for further research targeted at assessing 
the efficacy and safety of linezolid in HIV patients as they 
are more likely to develop active TB and TB-related mor-
tality rates among them remains higher than the general 
population [59]. Also, better data would be needed to 
evaluate for instance treatment duration that optimally 
balances favorable clinical outcomes but minimizes 
occurrence of adverse effects to improve patient safety. 
Furthermore, while an earlier RCT conducted by Paday-
atchi et al. [60] was challenged by patient recruitment and 
retention, this has been overcome by a successfully con-
ducted RCT by Tang et al. [51] while the sample size was 
relatively small, results from this RCT showed significant 
treatment success in the treatment group compared to the 
control group (p =  0.013). Nevertheless, there is urgent 
need for highly powered RCTs with larger sample size 
across highly endemic regions including participants from 
Africa to better inform the magnitude and significance of 
linezolid treatment effect in MDR and XDR TB patients.
Conclusions
Evidence available mainly from observational studies 
has demonstrated linezolid to be effective in the treat-
ment of MDR/XDR TB. This presents the drug as a via-
ble option towards effective pharmacotherapy for MDR/
XDR TB which is increasingly becoming a global health 
challenge. Nonetheless, patients ought to be monitored 
closely for the incidence of major adverse events such as 
myelosuppression and neuropathy. To minimize adverse 
effects and improve clinical outcomes, a combined high 
dose (1200 mg daily) for an intensive phase followed by 
a lower dose (300–600 mg daily) for a continuous phase 
is proposed along with effective patient monitoring to 
inform dose adjustments when required. This may how-
ever require thorough future research investigation. Spe-
cific TB guidelines incorporating the use of linezolid are 
required and wider commitments from all global health 
players are needed to address barriers such as the high 
cost of the drug if successful use and accessibility is to 
be achieved particularly in low-resourced settings where 
majority of TB patients live.
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